Risankizumab (RZB), humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, superior to PBO in PsA. Initial phase 2 results. No new safety signals noted. https://t.co/Jv1zpcg5Zd
#ACR19 @RheumNow abs#2877
Links:
Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of…
http://ow.ly/FZuD50x3BOh
Nov-13-2019
